4.6 Article

An International Model to Predict Recurrent Cardiovascular Disease

期刊

AMERICAN JOURNAL OF MEDICINE
卷 125, 期 7, 页码 695-+

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2012.01.014

关键词

Acute coronary syndromes; Cardiovascular disease; Cerebrovascular disease/stroke; Coronary disease; Mortality; Peripheral vascular disease; Risk factors

资金

  1. sanofi-aventis
  2. Bristol-Myers Squibb
  3. Waksman Foundation (Tokyo, Japan)
  4. Pfizer
  5. Amarin
  6. AstraZeneca
  7. Eisai
  8. Ethicon
  9. Medtronic
  10. Medicines Company
  11. National Heart, Lung, and Blood Institute
  12. R.W. Johnson Foundation
  13. GlaxoSmithKline
  14. Fournier
  15. Bayer
  16. Merck
  17. AGA Medical
  18. Boehringer Ingelheim
  19. Novo Nordisk
  20. Photo Thera
  21. Schering Plough
  22. MSD
  23. MSD-SP
  24. Astellas
  25. Daiichi-Sankyo
  26. Kowa
  27. Novartis
  28. Otsuka
  29. Schering-Plough
  30. Takeda
  31. Ono
  32. Eli Lilly
  33. Abiomed
  34. Data-scope
  35. Inovise
  36. Liposcience
  37. Response Biomedical
  38. Savacor
  39. CV Therapeutics
  40. Servier
  41. Nycomed

向作者/读者索取更多资源

BACKGROUND: Prediction models for cardiovascular events and cardiovascular death in patients with established cardiovascular disease are not generally available. METHODS: Participants from the prospective REduction of Atherothrombosis for Continued Health (REACH) Registry provided a global outpatient population with known cardiovascular disease at entry. Cardiovascular prediction models were estimated from the 2-year follow-up data of 49,689 participants from around the world. RESULTS: A developmental prediction model was estimated from 33,419 randomly selected participants (2394 cardiovascular events with 1029 cardiovascular deaths) from the pool of 49,689. The number of vascular beds with clinical disease, diabetes, smoking, low body mass index, history of atrial fibrillation, cardiac failure, and history of cardiovascular event(s) <1 year before baseline examination increased risk of a subsequent cardiovascular event. Statin (hazard ratio 0.75; 95% confidence interval, 0.69-0.82) and acetylsalicylic acid therapy (hazard ratio 0.90; 95% confidence interval, 0.83-0.99) also were significantly associated with reduced risk of cardiovascular events. The prediction model was validated in the remaining 16,270 REACH subjects (1172 cardiovascular events, 494 cardiovascular deaths). Risk of cardiovascular death was similarly estimated with the same set of risk factors. Simple algorithms were developed for prediction of overall cardiovascular events and for cardiovascular death. CONCLUSIONS: This study establishes and validates a risk model to predict secondary cardiovascular events and cardiovascular death in outpatients with established atherothrombotic disease. Traditional risk factors, burden of disease, lack of treatment, and geographic location all are related to an increased risk of subsequent cardiovascular morbidity and cardiovascular mortality. (C) 2012 Elsevier Inc. All rights reserved. . The American Journal of Medicine (2012) 125, 695-703

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据